Labels

Types of Vaccines for A Level Biology (9700): Live Attenuated, Inactivated & Conjugate Vaccines

Master the  Types of Vaccines for A Level Biology (9700): Live Attenuated, Inactivated & Conjugate Vaccines 

Our advanced study modules align perfectly with aligned with  Cambridge AS- A Level Biology (9700) appreciated at top-tier institutions like  Brampton Manor Academy (London),  Concord College (Shropshire)  Westminster School (London), Cardiff Sixth Form College (Wales / London) Dubai College, Tanglin Trust, aur German Swiss International School—these resources are designed to simplify complex concepts and guarantee top grades in your board examinations.

​​Before diving into Types of Vaccines for A Level Biology (9700): Live Attenuated, Inactivated & Conjugate Vaccines ensure you have gone through our previous guide : Stem Cells & Cell Differentiation: Potency, iPSCs & Medical Applications | Cambridge AS-Level Biology (9700)

Table of content
  • What is a Vaccine? (Artificial Active Immunity)
  • Attenuated Vaccine
    • Method of Preparation and Examples, 
    • Advantages and Disadvantages
  • Inactivated Vaccine
    • Method of Preparation and Examples,
    • Advantages and Disadvantages
  • Conjugate Vaccine - Method of Preparation
    • Method of Preparation and Examples,
    • Advantages and Disadvantages
  • Comparison Table between Attenuated, inactivated and Conjugated vaccine
  • AO1 Knowledge with Understanding (Direct & Recall Questions)
  • AO2 Application of Knowledge (Diagram & Labeling Questions)
  • AO3 Experimental Skills & Data Interpretation (Graph & Table Questions)
What is a Vaccine? (Artificial Active Immunity)
  • Vaccine is a harmless pathogen that is able to induce the immune system.
  • Vaccines are isolated from disease-causing microorganisms. The vaccine is injected into the bloodstream where it produces antibodies by using our B cells of blood.
Different types of vaccines 

  • These antibodies neutralise or inactivate the antigen ( foreign protein) Due to this , this response to encounter of antigen produces memory cells and is ready to produce a quick immune response by our immune system against the antigen. Vaccination is a form of Artificial Active Immunity.
  • Vaccine is artificial Because immunity is induced by deliberate injection of antigens, not by natural infection.
  • Vaccine is active Because the person's own immune system is stimulated to produce its own memory B and T cells and antibodies. It gives long-term protection but takes a few weeks to develop.
💡Read more to understand about the Introduction to Infectious Diseases: Pathogens & Transmission Modes | Cambridge AS-Level Biology (9700)

Attenuated Vaccine

  • An attenuated vaccine contains living microorganisms (viruses or bacteria) that have been weakened or attenuated in the lab so it cannot cause disease in a healthy person.
  • It can still replicate, so it gives a strong and long-lasting immune response similar to natural infection

Attenuated Vaccine: Method of Preparation and Example

  • The steps involved in prepration of Attenuated Vaccine are as follows :
  • ​Serial Passage in Foreign Hosts: The wild-type virulent strain is isolated from a patient and repeatedly cultured (passed) through non-human cells or foreign host environments (such as chick embryos, monkey kidney cells, or sub-optimal growth temperatures).
  • ​Adaptive Mutations: As the pathogen adapts to replicate efficiently in the foreign host cells, it accumulates random genetic mutations.
  • ​Loss of Human Virulence: The mutated strain loses its adaptation for human cells. When reintroduced into humans, it replicates slowly enough for the immune system to clear it quickly while mounting a robust immune response.
  • ​Recombinant DNA Methods (Modern): Targeted genetic engineering isolates the pathogen and selectively mutates or deletes specific virulence genes, making reversion to wild-type impossible. 

Flow chart to understand the prepration of Attenuated Vaccine 
​

Classic Examples

  • ​Viral: MMR (Measles, Mumps, Rubella), Oral Polio Vaccine (OPV / Sabin strain), Varicella (Chickenpox), Yellow Fever, and Rotavirus.
  • ​Bacterial: BCG (Bacillus Calmette-Guérin for Tuberculosis) and Oral Typhoid vaccine (Ty21a).
Advantages  of Attenuated Vaccine :

  • Long-Lasting Protection: It Often confers lifelong or multi-decade immunity with only 1 or 2 doses without requiring frequent boosters.
  • Herd Immunity Contribution: Some live strains (like oral polio) can shed temporarily in feces, indirectly immunizing close contacts.

Disadvantages of Attenuated Vaccine:

  • Reversion to Virulence: Rare risk of attenuated strains mutating back into virulent forms (e.g., vaccine-derived poliovirus from OPV).
  • Contraindicated in Immunocompromised: Can cause uncontrolled systemic infection in individuals with weakened immune systems (e.g., HIV/AIDS, chemotherapy patients).
  • Strict Cold Chain Requirements: Living pathogens are heat-sensitive and require continuous refrigeration/freezing during transport and storage.


Inactivated Vaccine or Killed vaccine

  • Inactivated vaccines (or killed vaccines) are prepared by destroying the pathogen's ability to replicate while keeping its surface antigens intact so the immune system can still recognize them and produce antibodies.

Inactivated Vaccine: Method of Preparation and Example

  • Culturing: The target pathogen (virus or bacterium) is grown in large quantities using cell cultures or nutrient media.
  • Inactivation: The pathogen is treated with chemical agents—most commonly formaldehyde or beta-propiolactone—or physical methods like heat/gamma radiation.
  • Structure Preservation: The nucleic acids (DNA/RNA) are destroyed to prevent replication, but the tertiary structure of surface antigens is preserved so lymphocytes can recognize them.
  • Purification & Adjuvants: The inactivated pathogens are purified and often combined with an adjuvant (e.g., aluminium salts) to enhance the immune response.

Inactivated Vaccine : Mechanism of Action 

Classic Examples : 

  • Polio: Salk vaccine (Inactivated Polio Vaccine / IPV)
  • ​Influenza: Standard seasonal flu shot 
  • Rabies: Rabies vaccine
  • ​Hepatitis A: Inactivated Hepatitis A vaccine
  • ​Cholera: Whole-cell inactivated cholera vaccine

Advantages  of Inactivated Vaccine :

  • It Cannot replicate or revert to a virulent form; completely safe for immunocompromised individuals.
  • This is more thermally stable than live attenuated vaccines; easier to store and transport in warm climates.
  • It Stimulates effective humoral immunity (B cells and neutralizing antibodies).
  • It has Zero risk of causing the disease in the host.
Disadvantages  of Inactivated Vaccine 
  • It requires strict quality control during manufacturing to ensure 100% pathogen inactivation.
  • It Produces a weaker immune response compared to live attenuated vaccines.
  • It Mainly stimulates humoral immunity; provides minimal cell-mediated immunity (TC cells).
  • Immune memory wanes  over time, requiring booster doses and adjuvants to maintain protection.

Conjugate Vaccine 
  • Conjugate vaccines are specialized vaccines created by chemically bonding a weak antigen (typically a bacterial capsular polysaccharide) to a strong carrier protein. 
  • Certain bacteria disguise themselves with an outer capsule of polysaccharides, which fails to trigger a strong immune response especially in infants and young children. 
  • Conjugating the polysaccharide to a protein converts the immune response from T-cell independent to T-cell dependent. 
Conjugate Vaccine: Method of Preparation and Example
  • Polysaccharide Extraction: The outer capsular polysaccharide antigens are isolated and purified from the cultured pathogenic bacteria.
  • Selection of Carrier Protein: A highly immunogenic protein is selected as the carrier (e.g., inactivated Diphtheria toxoid, Tetanus toxoid, or Mutant Diphtheria protein CRM197).
  • ​Chemical Activation & Coupling: The polysaccharide chains are chemically activated (often using linkers like cyanogen bromide or reductive amination) and covalently bonded to the surface amino acid residues of the carrier protein.
  • ​Purification: Unreacted polysaccharides and free carrier proteins are removed via centrifugation or filtration to yield the pure conjugate product.
  • ​Mechanism in the Body: Specific B-cells recognize the polysaccharide component, internalize the entire conjugate molecule, and present the processed carrier protein peptides on MHC Class II molecules to helper T-cells (TH). This T-cell help stimulates class-switching, affinity maturation, and memory cell formation.
Conjugate Protein 

​
Key Examples
  • ​Hib Vaccine: Haemophilus influenzae type b conjugate vaccine (protects against bacterial meningitis and pneumonia).
  • ​Pneumococcal Conjugate Vaccine (PCV): e.g., PCV13 or PCV15 (against Streptococcus.
  • Meningococcal Conjugate Vaccine (MenACWY): Against strains of Neisseria meningitidis.

Advantages  of Conjugate  Vaccine :
  • It triggers a T-cell dependent response, producing long-lived Memory B-cells and Memory T-cells.
  • It has high efficacy in infants and children under 2 years (whose immature immune systems cannot respond well to plain polysaccharides).
  • It promotes immunoglobulin class-switching (from low-affinity IgM to high-affinity IgG).
  • It reduces nasal and throat colonization of the bacteria, preventing transmission to non-vaccinated populations.
Disadvantages  of Conjugate  Vaccine :
  • This vaccine has complex, multi-step chemical manufacturing process makes them expensive to produce.
  • It has limited coverage,  only protects against the specific bacterial capsular serotypes included in the formulation.
  • It requires strict temperature-controlled storage (cold chain) to prevent protein denaturation.
  • It also requires multiple primary and booster doses to build and sustain protective antibody titers.
Comparison Table between Attenuated, inactivated and Conjugated vaccine
Feature Live Attenuated Vaccines Inactivated Vaccines Conjugate Vaccines
Nature of Pathogen Weakened, living pathogen capable of replication. Killed/inactivated whole pathogen (cannot replicate). Polysaccharide antigen chemically linked to a carrier protein.
Type of Immune Response Strong Humoral and Cell-Mediated immunity (stimulates $T_C$ and $T_H$ cells). Primarily Humoral immunity (antibody-mediated). Minimal cell-mediated response. Converts T-cell independent response into T-cell dependent response.
Efficacy in Infants (<2 yrs) Highly effective. Effective. Highly effective (specially designed for immature infant immune systems).
Immune Memory & Boosters Long-lasting memory; usually requires 1 or 2 doses (often no booster needed). Shorter-lived memory; requires booster doses over time. Produces long-term memory B and T cells; requires primary series and boosters.
Safety & Reversion Risk Risk of reverting to virulent form; unsafe for immunocompromised individuals. Zero risk of disease/reversion; completely safe for immunocompromised. Extremely safe; zero risk of infection since no whole pathogen is used.
Stability & Storage Requires strict cold chain (less stable at room temperature). More thermally stable; easier to transport and store in warm climates. Requires refrigeration to prevent protein carrier denaturation.
Production Cost & Complexity Relatively low cost once attenuation method is established. Moderate cost; relies on growing large volumes of live pathogen safely. High cost & complex chemical synthesis and purification process.
Key Examples MMR (Measles, Mumps, Rubella), Sabin OPV (Polio), BCG (Tuberculosis). Salk IPV (Polio), Seasonal Flu shot, Rabies, Hepatitis A. Hib (*Haemophilus influenzae* type b), PCV (Pneumococcal), MenACWY (Meningococcal).

Key Takeaways for Exams:
  • ​Live Attenuated Vaccines: Pathogen is weakened; triggers both humoral and cell-mediated immunity; high efficacy but poses a risk for immunocompromised individuals.
  • ​Inactivated Vaccines: Pathogen is killed; extremely safe with no replication risk; primarily stimulates humoral immunity and usually requires booster doses.
  • ​Conjugate Vaccines: Polysaccharide antigen bound to a protein carrier; converts T-cell independent response into T-cell dependent response; highly effective in infants under 2 years.

📝AO1 Knowledge with Understanding (Direct & Recall Questions)
Question 1: What is a live-attenuated vaccine, and how does it generate immunity in the body? ​Answer: A live-attenuated vaccine contains a weakened (attenuated) version of the living pathogen (virus or bacterium) that has lost its ability to cause disease but can still replicate slowly within the host. ​
It generates immunity by mimicking a natural infection. As the weakened pathogen replicates, it activates both humoral immunity (antibody production by B cells) and cell-mediated immunity (activation of cytotoxic T cells via MHC Class I pathway), leading to the formation of long-lasting memory cells. ​
Question 2: Define an inactivated vaccine and state one primary advantage and one disadvantage of this vaccine platform. ​Answer: An inactivated vaccine (killed vaccine) is made from a pathogen that has been rendered non-viable (killed) using physical methods (such as heat) or chemical agents (such as formalin or formaldehyde) so that it cannot replicate or cause infection. ​
Advantage: Highly safe and stable; it carries zero risk of reverting to a virulent form, making it safe for immunocompromised individuals. ​
Disadvantage: It generally produces a weaker immune response (primarily humoral immunity without cell-mediated immunity) and typically requires multiple booster doses to maintain long-term protection.
​Question 3: Explain what a conjugate vaccine is and why it is specifically used against encapsulated bacteria. ​Answer: A conjugate vaccine is a type of subunit vaccine created by chemically linking a weak antigen—specifically a polysaccharide capsule from a bacterium—to a strong, immunogenic carrier protein (such as tetanus toxoid). ​
Encapsulated bacteria (e.g., Streptococcus pneumoniae) have polysaccharide coats that stimulate T-cell-independent immune responses, which are weak in infants and fail to produce memory B cells.

By attaching the protein carrier, T cells recognize the protein fragment, converting the response into a T-cell-dependent pathway. This triggers robust antibody production and immune memory formation, even in young children.
​
Question 4: Complete the recall matrix by identifying the vaccine platform for each listed pathogen. Answer :
1. MMR (Measles, Mumps, Rubella) : Live-Attenuated Vaccine 2. Salk Polio Vaccine : (IPV)Inactivated Vaccine 3. Hib (Haemophilus influenzae type b) : Conjugate Vaccine 4. BCG (Tuberculosis)Live : Attenuated Vaccine 📝AO2 Application of Knowledge (Diagram & Labeling Questions)

Context: 1 Study the following diagram and gives answer of the following questions :



Question 1: Identify the vaccine types represented by labels A, B, C, and D in the diagram.
Question 2: Compare the immunological pathways activated by Vaccine A versus Vaccine B upon administration.
Question 3 : Explain why Vaccine A is strictly contraindicated in patients undergoing systemic chemotherapy or those with severe immunodeficiency, whereas Vaccine B or C can be safely administered.
Question 4 : State the role of the genetic material labeled "DNA and RNA" in modern nucleic acid vaccine platforms. Answer: 1 ​A: Attenuated (Live-Attenuated) Vaccine (Notice mutated genome inside replicating structure) ​B: Inactivated (Killed) Vaccine (Notice non-replicating/modified structural form) ​C: Subunit / Protein Subunit Vaccine (Notice isolated surface antigen/spike protein) ​D: Viral Vector Vaccine (Notice target antigen gene inserted into a different carrier virus) ​ Answer 2 : ​Vaccine A (Live-Attenuated): Replicates inside host cells. Antigens are presented on MHC Class I molecules, which triggers a robust Cell-Mediated Immune Response (Cytotoxic T cells / Tc) in addition to a Humoral Response (B cells / Antibodies) via MHC Class II. ​Vaccine B (Inactivated): Cannot replicate and is processed as an exogenous antigen via MHC Class II molecules. It primarily stimulates a Humoral Immune Response (B-cell activation and antibody production), requiring adjuvants and boosters for long-term protection. Answer 3 : Vaccine A contains live, replicating pathogens. In immunocompromised individuals, the host immune system cannot restrict even weakened replication, leading to unchecked viral spread and severe clinical disease. Vaccines B and C are non-replicating/non-living and carry zero risk of disease replication. Answer 4 : DNA and RNA (Nucleic Acid) Vaccines deliver genetic instructions directly into host cells, forcing human muscle/dendritic cells to transiently synthesize the viral antigen endogenously, triggering both MHC-I and MHC-II immune pathways without using live pathogens. ​
Context 2: Study the following diagram and answer the following questions:



Question 1 :  Identify process/structure X and molecules Y shown in the second diagram.

Question 2 : Describe the step-by-step biological mechanism occurring from stage X to the production of Y in a human lymph node.

Question 3 : Sketch or describe the graph of Antibody (Y) concentration over time following the first exposure to X versus a second exposure to the same live pathogen 6 months later.

Question 4:  Explain the cellular basis for the difference in response time and antibody titer between the primary and secondary exposures.

Answer 1 : X: Attenuated / Weakened Pathogen (or Inactivated Pathogen being processed by Host Antigen-Presenting Cells).
​Y: Antibodies (Immunoglobulins) secreted by Plasma Cells. ​
Answer 2: Antigen Processing: The modified/weakened pathogen X is engulfed by Antigen-Presenting Cells (APCs, e.g., Dendritic cells/Macrophages) via phagocytosis or endocytosis. ​
Antigen Presentation: APCs process pathogen surface proteins and display epitope fragments on MHC Class II cell surface receptors. ​
Helper T-Cell Activation: Naïve T_H cells bind to the MHC-II-antigen complex via T-cell receptors (TCR) and undergo activation and clonal expansion.
​B-Cell Selection & Plasma Cell Differentiation: Activated T_H cells release cytokines (e.g., IL-4, IL-21) to stimulate specific B-lymphocytes. B cells differentiate into Plasma Cells (which secrete Y - Antibodies) and long-lived Memory B Cells.

Answer 3 :

Answer 4 : The primary exposure forms pool of antigen-specific Memory B and T Lymphocytes. Upon secondary exposure, these memory cells recognize the antigen immediately without requiring lengthy clonal selection, rapidly proliferating into functional plasma cells to produce large volumes of high-affinity antibodies.

📝AO3 Experimental Skills & Data Interpretation (Graph & Table Questions)

Context 1 : An investigation was conducted to compare the efficacy and antibody dynamics of three different COVID-19 vaccine platforms (Live-Attenuated, Inactivated, and mRNA) during clinical trials.
​
The table below shows the mean neutralizing antibody titer (measured in Arbitrary Units per mL) and observed clinical efficacy against symptomatic infection over a 12-month period post-vaccination.
Vaccine Platform Primary Doses Mean Antibody Titer at Day 14 (AU/mL) Peak Mean Antibody Titer (AU/mL) Mean Antibody Titer at Month 12 (AU/mL) Efficacy against Symptomatic Infection (Month 1) Efficacy against Symptomatic Infection (Month 12)
Vaccine A (Live-Attenuated) 1 450 1,800 (Day 28) 1,250 91% 84%
Vaccine B (Inactivated) 2 120 850 (Day 14 post-dose 2) 180 78% 42%
Vaccine C (mRNA Subunit) 2 820 3,400 (Day 14 post-dose 2) 610 95% 68%

Questions 1 :  Calculate the percentage decrease in efficacy from Month 1 to Month 12 for Vaccine B compared to Vaccine A.

Question 2 :  Based on the data, evaluate which vaccine platform provides the most durable (long-lasting) protection. Justify your answer using specific figures from the table.

Question 3 :  Explain why Vaccine C produces a significantly higher peak antibody titer at Day 14 post-dose 2 compared to Vaccine B.

Answer 1 :  ​Vaccine B drop: 78% - 42% = 36% drop. 
Percentage decrease =( 78 - 42) x 100  / 78 = 46.15%
​Vaccine A drop: 91% - 84% = 7% drop. Percentage decrease = ( 91 - 84) x 100 / 91=  7.69%

​Answer 2 :  ​Vaccine A (Live-Attenuated) provides the most durable protection.
​Justification: At Month 12, Vaccine A retains 69.4% of its peak antibody titer (1,250 / 1,800), whereas Vaccine B retains only 21.2% (180 / 850) and Vaccine C retains 17.9% (610 / 3,400). Furthermore, Vaccine A's clinical efficacy drops by only 7%  from 91% to 84% , maintaining high protection over 12 months with a single dose.

​Answer 3 :  ​mRNA vaccines (Vaccine C) force host muscle/dendritic cells to synthesize viral antigens endogenously, presenting antigens via both MHC Class I and MHC Class II pathways.
​
This leads to stronger activation of TH cells and robust B-cell proliferation into short-lived plasma cells, resulting in massive initial antibody secretion compared to inactivated whole-virus antigens (Vaccine B), which are exogenous and less immunogenic without strong adjuvants.

​Context 2 : A group of researchers wants to test the effect of storage temperature on the viability and immunogenicity of a newly developed Live-Attenuated Measles Vaccine.
​
Questions: 1  State the Independent Variable, Dependent Variable, and TWO Controlled Variables for this experiment.

Question: 2  Outline a step-by-step experimental method to measure how thermal degradation affects viral viability (plaque-forming units, PFU/mL) over 30 days.

Question 3 : Predict the outcome if the attenuated vaccine is stored at 25 degree celsius (room temperature) for 14 days without a cold chain, and explain the molecular reason behind this change.
​
Answer 1 :  ​Independent Variable: Storage temperature (e.g., -20 degree celsius, 4 degree celsius , 25 degree celsius, and 37 degree celsius.
​Dependent Variable: Concentration of viable viral particles measured as Plaque-Forming Units per milliliter .
​Controlled Variables: Light exposure (kept in dark), batch/lot of vaccine, volume of vaccine solution per vial, pH of storage buffer solution.

​Answer 2 :  Aliquot equal volumes (1.0  mL of the same vaccine batch into sterile, sealed glass vials.
​
Incubate sets of vials at target temperatures -20 degree celsius, 4 degree celsius , 25 degree celsius, and 37 degree celsius in dark incubators.
​At 5-day intervals (Days 0, 5, 10, 15, 20, 25, 30), take three replicate samples from each temperature group.
​
Perform a serial dilution  and inoculate confluent monolayer cultures of susceptible host cells (e.g., Vero cells).
​Count viral plaques after incubation, calculate mean PFU/mL,   and plot a line graph of Viral Viability (PFU/mL) vs. Time (Days) for each temperature.

​Answer 3 : Prediction: The viral viability (PFU/mL}) will drop sharply near zero within 14 days at 25 degree Celsius .
​Molecular Reason: Live-attenuated viruses rely on intact viral envelope lipids and folded capsids/surface glycoproteins. Higher temperatures thermal-denature surface spikes (hemagglutinin/fusion proteins) and disrupt the viral lipid envelope, rendering the virus incapable of binding to host cell receptors.

Context 3 : Study the graphs given below and answer the following questions based on the graphs .



Question : 1  State what the dashed horizontal line labeled "Protective antibody level" represents in terms of clinical immunity.

Question 2 :  Compare the immune response shown in Graph A with the primary response in Graph B after initial vaccine exposure.

Question 3 : Explain why the slope of the curve is significantly steeper following Pathogen exposure compared to Vaccine exposure in Graph B.

Question 4 :  Identify the specific immune cell types responsible for the rapid rise in antibody titer during the Secondary immune response. 

 
Answer 1 : ​Protective antibody level represents the minimum serum concentration of specific antibodies required to successfully neutralize the pathogen and prevent symptomatic infection or disease transmission in the host.  
​
Answer 2 :  ​In Graph A, a single vaccine exposure triggers a robust primary immune response that maintains antibody levels permanently above the protective threshold, conferring long-term protection without needing a secondary exposure.  
​
In Graph B, the initial vaccine exposure produces a primary response where antibody levels eventually drop below the protective threshold, requiring either a booster or natural pathogen exposure to restore protective immunity.

Answer 3 : ​The first exposure (Vaccine exposure) involves naïve B lymphocytes undergoing a slow process of clonal selection, expansion, and differentiation into plasma cells (taking 7–10 days).  
​The second exposure (Pathogen exposure) activates pre-existing Memory B cells. These cells recognize the antigen immediately, proliferating rapidly without a lag phase, leading to a much steeper rise in antibody concentration.  
​
Answer 4 : ​Memory B Lymphocytes (which rapidly differentiate into high-output Plasma cells upon restimulation) and Memory Helper T cells (TH).

This module is developed by Grip the Biology for NEET Biology, IGSCE & IB  Biology students. Search "Grip the  Biology" on Google for more resources.

🎯 Take Your Biology Prep to the Next Level! ​

Struggling with complex Cambridge 9700/AP Biology data evaluation, graphs, or past papers? 

Don't worry, you don't have to study alone. ​Book a Free 1-on-1 Live Whiteboard Demo Session with me. 

We will break down tough concepts together in real-time.​👇 Click the WhatsApp button below right now to claim your free slot!



🚀 Next Steps

More Biology Hub Pages !

❓ In case of any doubt, Chat Directly: 💬 Ask Your Doubt on WhatsApp

Share with the Friends 🙂
Labels:

Comments

Post a Comment